Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs SIBN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SIBN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–0 Matrix Metrics)

SIBN Overall Winner 6-Pillar Tally: AXNX 0 – 5 SIBN (1 Tie) Matrix Metrics: AXNX 0 – 8 SIBN

As of Nov 20, 2026, SI-BONE, Inc. (SIBN) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas SIBN carries 53.5/100 (HOLD) at $23.73 (N/M Forward P/E, -7.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs SIBN
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
SIBN NASDAQ Head-to-Head Winner
SI-BONE, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$23.73
-0.08% 1D
Market Cap $1.1B
TTM Revenue $221M
Forward P/E N/M
Beta / 30D Vol 0.65β · 74% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 72.0 Mom 56.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.9% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $23.32 · SMA50: $20.88

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 5 SIBN)

Columns: Metric · AXNX · SIBN
1. Valuation Multiples SIBN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 4.9x
2. Growth & Scale SIBN
Revenue Growth (YoY) N/A +14.5%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $221M
Market Cap N/A $1.1B
3. Profitability & Quality SIBN
Gross Margin N/A 79.4%
Operating Margin N/A -7.6%
Net Profit Margin N/A -6.2%
Return on Equity (ROE) N/A -7.7%
4. Balance Sheet & Cash Flow SIBN
Cash Generation (TTM) N/A -$4.2M
Cash Flow Margin N/A -1.9%
Net Cash / Leverage N/A ROE $7.5M Net Debt (0.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIBN
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 149.2% (48th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (0) vs SIBN (8)
Institutional Metric AXNX SIBN Criterion Row Edge
Market Capitalization
Scale
N/A $1.1B Larger Scale SIBN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +14.5% Higher Growth SIBN
Operating Margin (TTM)
Profitability
N/A -7.6% Higher Margin SIBN
Net Profit Margin
Profitability
N/A -6.2% Higher Margin SIBN
Return on Equity (ROE)
Capital Efficiency
N/A -7.7% Higher ROE SIBN
52-Week Range Position
Momentum
50% ($0–$1) 85% ($11–$26) Stronger Trend SIBN
Beta / 30D Volatility
Risk Regime
N/A 0.65β · 74% Vol Lower Realized Risk SIBN
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite SIBN
Trailing 12M Revenue (USD)
Operating Scale
N/A $221M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 79.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$4.2M ($7.5M Net Debt (0.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SIBN +36.6 pp
AXNX: -26.54% · SIBN: +10.06%
3M Horizon SIBN +3.66 pp
AXNX: +16.92% · SIBN: +20.58%
6M Horizon SIBN +3.66 pp
AXNX: +16.92% · SIBN: +20.58%
1Y Horizon SIBN +3.66 pp
AXNX: +16.92% · SIBN: +20.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs SIBN. Trailing 12-month operating profitability (AXNX N/A vs SIBN -7.6%) and valuation multiples (AXNX N/M vs SIBN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SIBN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$221M
Gross Margin79.4%
Op. Margin-7.6%
ROE / Fwd P/E-7.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIBN BREAKOUT
78d in phase · OBV DISTRIBUTION
Current IV 149.2%
IV Percentile 48th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SIBN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and -7.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs SIBN Key Questions & Quantitative Answers

As of Nov 20, 2026, SI-BONE, Inc. (SIBN) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas SIBN carries 53.5/100 (HOLD) at $23.73 (N/M Forward P/E, -7.6% operating margin). Technically, AXNX sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and SIBN sits in a Markup phase (RSI 57.6, BREAKOUT options structure).

SIBN leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SIBN at +14.5% YoY revenue growth and +0.0% YoY earnings growth on $221M TTM revenue (79.4% gross margin, -7.6% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $221M for SIBN. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SIBN.

SIBN screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SIBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (-1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus SIBN (-7.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, SIBN carries 149.2% implied volatility (48th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (0.65β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.